Search research articles
Contact Us
Filters
Showing results (21-30 of 360) with videos related to
Page
of 36
Sort By:
The New England Journal of Medicine
|
January 29, 2005
Caspofungin versus liposomal amphotericin B for empirical therapy
Pierre Tattevin, Benoît Bareau, Christophe Camus
La Revue Du Praticien
|
December 5, 2018
[Treatment of tuberculosis: what's new?]
Matthieu Revest, Marion Baldeyrou, Pierre Tattevin
The American Journal of Medicine
|
January 3, 2015
The reply
Pierre Fillatre, Matthieu Revest, Pierre Tattevin
The New England Journal of Medicine
|
April 23, 2020
Prevention of Early Ventilator-Associated Pneumonia
Nicolas Massart, Pierre Fillatre, Pierre Tattevin
Heart (British Cardiac Society)
|
May 10, 2017
Machine learning to support decision-making for cardiac surgery during the acute phase of infective endocarditis
Erwan Donal, Erwan Flecher, Pierre Tattevin
The New England Journal of Medicine
|
November 12, 2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission
Pierre Tattevin, Cédric Arvieux, Christian Courpotin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2009
Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias
Pierre Tattevin, Fabrice Uhel, Fabien Fily
Archives of Internal Medicine
|
January 27, 2010
Can we really achieve a 1-year mortality rate lower than 10% in patients with infective endocarditis?
Pierre Tattevin, Erwan Donal, Matthieu Revest
Research in Microbiology
|
April 16, 2009
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response
Pierre Tattevin, Li Basuino, Henry F Chambers
La Revue Du Praticien
|
January 16, 2014
[Antibiotic prescription and surveillance]
Solène Patrat-Delon, Matthieu Revest, Pierre Tattevin
Page
of 36
Search research articles
Search
Showing results (21-30 of 360) with videos related to
Sort By:
Page
of 36
The New England Journal of Medicine
|
January 29, 2005
Caspofungin versus liposomal amphotericin B for empirical therapy
Pierre Tattevin, Benoît Bareau, Christophe Camus
La Revue Du Praticien
|
December 5, 2018
[Treatment of tuberculosis: what's new?]
Matthieu Revest, Marion Baldeyrou, Pierre Tattevin
The American Journal of Medicine
|
January 3, 2015
The reply
Pierre Fillatre, Matthieu Revest, Pierre Tattevin
The New England Journal of Medicine
|
April 23, 2020
Prevention of Early Ventilator-Associated Pneumonia
Nicolas Massart, Pierre Fillatre, Pierre Tattevin
Heart (British Cardiac Society)
|
May 10, 2017
Machine learning to support decision-making for cardiac surgery during the acute phase of infective endocarditis
Erwan Donal, Erwan Flecher, Pierre Tattevin
The New England Journal of Medicine
|
November 12, 2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission
Pierre Tattevin, Cédric Arvieux, Christian Courpotin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2009
Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias
Pierre Tattevin, Fabrice Uhel, Fabien Fily
Archives of Internal Medicine
|
January 27, 2010
Can we really achieve a 1-year mortality rate lower than 10% in patients with infective endocarditis?
Pierre Tattevin, Erwan Donal, Matthieu Revest
Research in Microbiology
|
April 16, 2009
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response
Pierre Tattevin, Li Basuino, Henry F Chambers
La Revue Du Praticien
|
January 16, 2014
[Antibiotic prescription and surveillance]
Solène Patrat-Delon, Matthieu Revest, Pierre Tattevin
Page
of 36